AMRX vs IONS: stock comparison and AI forecast
Amneal Pharmaceuticals, Inc. (AMRX) and Ionis Pharmaceuticals Inc (IONS) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
AMRX Amneal Pharmaceuticals, Inc.
- Price
- $20.21 +50.7% · 6M
- Market Cap
- $6.45B
- P/E Ratio
- 61.2x
- Size
- mid-cap
- AI Forecast
IONS Ionis Pharmaceuticals Inc
- Market Cap
- $7.23B
- P/E Ratio
- –
- Size
- mid-cap
- AI Forecast
- NO CURRENT FORECAST
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- IONS is 1.1 times larger than AMRX by market capitalization ($7.23B against $6.45B).
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | AMRX | IONS |
|---|---|---|
| Market Cap | $6.45B | $7.23B |
| P/E Ratio | 61.24x | – |
| P/B Ratio | – | 16.45x |
| EPS | $0.33 | $-3.77 |
| Book Value/Share | – | $2.65 |
| Revenue/Share | $9.76 | $1.60 |
| FCF/Share | $0.40 | $-3.37 |
Profitability & Margins
| Metric | AMRX | IONS |
|---|---|---|
| ROE | – | -128.5% |
| ROA | – | -18.9% |
| ROIC | – | -22.2% |
| Gross Margin | 39.3% | 94.0% |
| Operating Margin | – | -224.0% |
| Net Margin | – | -213.0% |
| EBT Margin | – | -211.8% |
| Tax Rate | -7.0% | -0.6% |
Financial Health
| Metric | AMRX | IONS |
|---|---|---|
| Current Ratio | 2.20x | 7.89x |
| Quick Ratio | 1.44x | 7.73x |
| D/E Ratio | – | 5.81x |
| Financial Leverage | – | 6.81x |
| Interest Coverage | 3.7x | -22.1x |
| Working Capital | $1.06B | $2.18B |
Cash Flow
| Metric | AMRX | IONS |
|---|---|---|
| Operating Cash Flow | $201M | -$496M |
| Free Cash Flow | $128M | -$561M |
| Capital Spending | -$73M | -$64M |
| OCF Growth YoY | -42.8% | – |
| FCF Growth YoY | -54.8% | – |
| FCF/Sales | 4.1% | -211.4% |
| CapEx/Sales | 2.3% | 24.3% |
Operational Efficiency
| Metric | AMRX | IONS |
|---|---|---|
| Asset Turnover | – | 0.09x |
| Inventory Turnover | 2.8x | 0.3x |
| Fixed Assets Turnover | 6.8x | 1.7x |
| Days Inventory | 131 days | 1158 days |
| Payables Period | – | 1087 days |
Income Statement
| Metric | AMRX | IONS |
|---|---|---|
| Total Revenue | $3.12B | $265M |
| Operating Income | $454M | -$594M |
| Net Income | $0.00M | -$565M |
| R&D Expense | $176M | – |
| SG&A Expense | $572M | $528M |
| Cost of Goods Sold | $1.89B | $16M |
Dividend & Shareholder Information
| Metric | AMRX | IONS |
|---|---|---|
| Shares Outstanding | 319M | 166M |
AMRX vs IONS: stock comparison and AI forecast
Which is bigger, AMRX or IONS?
IONS is 1.1 times larger than AMRX by market capitalization ($7.23B against $6.45B).
Which one does Intratio's AI model rank higher, AMRX or IONS?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.